论文部分内容阅读
据报道晚期卵巢癌用标准化疗方案的反应率和缓解率分别不到20％及10％,作者收集200多名晚期卵巢癌病人接受高剂量化疗方案辅以自体骨髓支持治疗(ABMS),结果表明对于顽固性卵巢癌效果明显,其反应率可达70％～82％,生存期有不同程度延长。 Shpall等人的给药方案:CTX5.6g/m~2,顺铂165mg/m~2,噻替派300mg/m~2。75％的病人肿瘤部份消失并经病理证实,化疗中毒副作用的致死率是20％。Mulder等人用药方案:CTX7.0g/m~2,VP-161.0～1.5g/m~2,辅以ABMS,75％伴微小肿瘤(<2cm)者平均15个月之后瘤体消失且有病理证实。DaulPlat等人先用高剂量肉瘤霉素140mg/m~2辅
It has been reported that advanced ovarian cancer with standard chemotherapy regimen and response rates were less than 20% and 10%, the authors collected more than 200 patients with advanced ovarian cancer receiving high-dose chemotherapy combined with autologous bone marrow support therapy (ABMS), the results show Obvious effect on refractory ovarian cancer, the response rate of up to 70% to 82%, the survival of varying degrees of extension. Shpall et al dosing regimen: CTX5.6g / m ~ 2, cisplatin 165mg / m ~ 2, thiotepa 300mg / m ~ 2.75% of the patient’s tumor disappeared and confirmed by pathology, chemotherapy poisoning side effects Mortality is 20%. Mulder et al dosing regimen: CTX7.0g / m ~ 2, VP-161.0 ~ 1.5g / m ~ 2, combined with ABMS, 75% with small tumors (<2cm) were 15 months after the tumor disappeared and pathological Confirmed. DaulPlat et al first with high-dose sarcosomycin 140mg / m ~ 2 supplements